The client
ENB Therapeutics a new company with an innovation with addressing the most difficult to treat tumors

The challenge
Showcased a new era in cancer therapy by communicating the potential for addressing the most difficult to treat tumors in a way that can be understood and appreciated by multiple audiences including investors

The result
They attracted Merck oncology who created a clinical trial with Keytruda. ENB Therapuetic’s ENB-003 + Ketruda demonstrated encouraging objective response, disease control and progression free survival with metastatic platinum refractory/resistant ovarian cancer. ENB received orphan drug designation for pancreatic cancer.

The elements
A new logo, website, investor presentation, MOA and medical illustrations as well as the overall visual identity introduced the company and its innovations to investors and potential partners